Financial Sense Advisors Inc. bought a new position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 40,900 shares of the company’s stock, valued at approximately $775,000.
A number of other institutional investors also recently added to or reduced their stakes in TEVA. Calton & Associates Inc. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $108,000. Penserra Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $129,000. Fieldpoint Private Securities LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $171,000. Global Financial Private Capital LLC bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $193,000. Finally, Wetherby Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $197,000. 49.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at $20.90 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.86 and a quick ratio of 0.58. The company has a market capitalization of $21,400.00, a PE ratio of -1.21, a price-to-earnings-growth ratio of 1.81 and a beta of 0.59. Teva Pharmaceutical Industries Ltd has a 1 year low of $10.85 and a 1 year high of $37.94.
Several equities research analysts have commented on the company. BTIG Research downgraded Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 target price on the stock. in a report on Friday, February 2nd. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Leerink Swann dropped their target price on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a report on Friday, February 9th. Piper Jaffray Companies downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 price target on the stock. in a report on Friday, February 9th. Finally, ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, February 15th. Ten research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $21.26.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.